25 XP   0   0   10

Lixte Biotechnology Holdings Inc
Buy, Hold or Sell?

Let's analyse Lixte together

PenkeI guess you are interested in Lixte Biotechnology Holdings Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Lixte Biotechnology Holdings Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Lixte Biotechnology Holdings Inc

I send you an email if I find something interesting about Lixte Biotechnology Holdings Inc.

Quick analysis of Lixte (30 sec.)










What can you expect buying and holding a share of Lixte? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
30.0%

What is your share worth?

Current worth
$1.78
Expected worth in 1 year
$-0.31
How sure are you?
60.0%

+ What do you gain per year?

Total Gains per Share
$-2.08
Return On Investment
-72.3%

For what price can you sell your share?

Current Price per Share
$2.88
Expected price per share
$2.61 - $4.4
How sure are you?
50%

1. Valuation of Lixte (5 min.)




Live pricePrice per Share (EOD)

$2.88

Intrinsic Value Per Share

$-26.07 - $-15.79

Total Value Per Share

$-24.30 - $-14.01

2. Growth of Lixte (5 min.)




Is Lixte growing?

Current yearPrevious yearGrowGrow %
How rich?$3.9m$5.1m-$1.1m-29.3%

How much money is Lixte making?

Current yearPrevious yearGrowGrow %
Making money-$5m-$6.3m$1.2m23.9%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Lixte (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#767 / 1007

Most Revenue
#769 / 1007

Most Profit
#255 / 1007

Most Efficient
#197 / 1007

What can you expect buying and holding a share of Lixte? (5 min.)

Welcome investor! Lixte's management wants to use your money to grow the business. In return you get a share of Lixte.

What can you expect buying and holding a share of Lixte?

First you should know what it really means to hold a share of Lixte. And how you can make/lose money.

Speculation

The Price per Share of Lixte is $2.88. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Lixte.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Lixte, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.78. Based on the TTM, the Book Value Change Per Share is $-0.52 per quarter. Based on the YOY, the Book Value Change Per Share is $0.17 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Lixte.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-2.26-78.5%-2.26-78.5%-2.80-97.3%-2.12-73.6%-1.58-54.8%
Usd Book Value Change Per Share-0.52-18.1%-0.52-18.1%0.175.8%-0.01-0.4%0.175.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.52-18.1%-0.52-18.1%0.175.8%-0.01-0.4%0.175.8%
Usd Price Per Share2.35-2.35-0.51-1.58-0.97-
Price to Earnings Ratio-1.04--1.04--0.18--0.89--0.62-
Price-to-Total Gains Ratio-4.52--4.52-3.05--2.34-1.69-
Price to Book Ratio1.32-1.32-0.22-0.83-1.07-
Price-to-Total Gains Ratio-4.52--4.52-3.05--2.34-1.69-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.88
Number of shares347
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.52-0.01
Usd Total Gains Per Share-0.52-0.01
Gains per Quarter (347 shares)-180.57-4.04
Gains per Year (347 shares)-722.27-16.18
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-722-7320-16-26
20-1445-14540-32-42
30-2167-21760-49-58
40-2889-28980-65-74
50-3611-36200-81-90
60-4334-43420-97-106
70-5056-50640-113-122
80-5778-57860-129-138
90-6500-65080-146-154
100-7223-72300-162-170

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.019.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%6.04.00.060.0%10.09.00.052.6%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%3.00.07.030.0%4.00.015.021.1%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%6.04.00.060.0%10.09.00.052.6%

Fundamentals of Lixte

About Lixte Biotechnology Holdings Inc

Lixte Biotechnology Holdings, Inc. operates as a clinical-stage biopharmaceutical company that uses biomarker technology to identify enzyme targets associated with serious common diseases. The company primarily focuses on inhibitors of protein phosphatase 2A that are used in combination with cytotoxic agents and/or x-ray, immune checkpoint blockers and other cancer therapies. It develops LB-100 that has completed phase I clinical trial for advanced soft tissue carcinoma and small cell lung cancer, as well as is in Phase II clinical trial for ovarian clear cell cancer. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; license agreements with National Institute of Health and Moffitt Cancer Center; and collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

Fundamental data was last updated by Penke on 2024-05-02 23:06:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Lixte Biotechnology Holdings Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Lixte earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Lixte to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Lixte Biotechnology Holdings Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-142.6%+142.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.2%+207.2%
TTM--218.5%+218.5%
YOY--282.4%+282.4%
5Y--432.2%+432.2%
10Y-142.6%-593.8%+451.2%
1.1.2. Return on Assets

Shows how efficient Lixte is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Lixte to the Biotechnology industry mean.
  • -118.1% Return on Assets means that Lixte generated $-1.18 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Lixte Biotechnology Holdings Inc:

  • The MRQ is -118.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -118.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-118.1%TTM-118.1%0.0%
TTM-118.1%YOY-113.4%-4.7%
TTM-118.1%5Y-103.1%-15.0%
5Y-103.1%10Y-217.9%+114.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-118.1%-13.2%-104.9%
TTM-118.1%-12.6%-105.5%
YOY-113.4%-11.5%-101.9%
5Y-103.1%-13.7%-89.4%
10Y-217.9%-15.5%-202.4%
1.1.3. Return on Equity

Shows how efficient Lixte is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Lixte to the Biotechnology industry mean.
  • -127.3% Return on Equity means Lixte generated $-1.27 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Lixte Biotechnology Holdings Inc:

  • The MRQ is -127.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -127.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-127.3%TTM-127.3%0.0%
TTM-127.3%YOY-122.1%-5.3%
TTM-127.3%5Y-110.7%-16.7%
5Y-110.7%10Y-373.4%+262.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-127.3%-16.7%-110.6%
TTM-127.3%-15.8%-111.5%
YOY-122.1%-14.4%-107.7%
5Y-110.7%-19.0%-91.7%
10Y-373.4%-19.9%-353.5%

1.2. Operating Efficiency of Lixte Biotechnology Holdings Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Lixte is operating .

  • Measures how much profit Lixte makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Lixte to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Lixte Biotechnology Holdings Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-132.3%+132.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.5%+286.5%
TTM--229.1%+229.1%
YOY--288.4%+288.4%
5Y--480.7%+480.7%
10Y-132.3%-624.7%+492.4%
1.2.2. Operating Ratio

Measures how efficient Lixte is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Lixte Biotechnology Holdings Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y1.423-1.423
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.231-3.231
TTM-3.307-3.307
YOY-3.774-3.774
5Y-5.667-5.667
10Y1.4237.558-6.135

1.3. Liquidity of Lixte Biotechnology Holdings Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Lixte is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 13.48 means the company has $13.48 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Lixte Biotechnology Holdings Inc:

  • The MRQ is 13.479. The company is very able to pay all its short-term debts. +2
  • The TTM is 13.479. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ13.479TTM13.4790.000
TTM13.479YOY14.084-0.604
TTM13.4795Y15.951-2.472
5Y15.95110Y11.002+4.949
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.4793.890+9.589
TTM13.4794.182+9.297
YOY14.0845.343+8.741
5Y15.9516.135+9.816
10Y11.0026.453+4.549
1.3.2. Quick Ratio

Measures if Lixte is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Lixte to the Biotechnology industry mean.
  • A Quick Ratio of 13.39 means the company can pay off $13.39 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Lixte Biotechnology Holdings Inc:

  • The MRQ is 13.393. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 13.393. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ13.393TTM13.3930.000
TTM13.393YOY13.560-0.167
TTM13.3935Y15.455-2.062
5Y15.45510Y10.519+4.936
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.3933.528+9.865
TTM13.3934.059+9.334
YOY13.5605.390+8.170
5Y15.4556.138+9.317
10Y10.5196.488+4.031

1.4. Solvency of Lixte Biotechnology Holdings Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Lixte assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Lixte to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.07 means that Lixte assets are financed with 7.3% credit (debt) and the remaining percentage (100% - 7.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Lixte Biotechnology Holdings Inc:

  • The MRQ is 0.073. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.073. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.073TTM0.0730.000
TTM0.073YOY0.071+0.002
TTM0.0735Y0.067+0.006
5Y0.06710Y0.214-0.148
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0730.339-0.266
TTM0.0730.337-0.264
YOY0.0710.273-0.202
5Y0.0670.368-0.301
10Y0.2140.391-0.177
1.4.2. Debt to Equity Ratio

Measures if Lixte is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Lixte to the Biotechnology industry mean.
  • A Debt to Equity ratio of 7.9% means that company has $0.08 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Lixte Biotechnology Holdings Inc:

  • The MRQ is 0.079. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.079. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.079TTM0.0790.000
TTM0.079YOY0.076+0.002
TTM0.0795Y0.072+0.007
5Y0.07210Y0.375-0.303
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0790.388-0.309
TTM0.0790.403-0.324
YOY0.0760.342-0.266
5Y0.0720.432-0.360
10Y0.3750.461-0.086

2. Market Valuation of Lixte Biotechnology Holdings Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Lixte generates.

  • Above 15 is considered overpriced but always compare Lixte to the Biotechnology industry mean.
  • A PE ratio of -1.04 means the investor is paying $-1.04 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Lixte Biotechnology Holdings Inc:

  • The EOD is -1.273. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.039. Based on the earnings, the company is expensive. -2
  • The TTM is -1.039. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.273MRQ-1.039-0.234
MRQ-1.039TTM-1.0390.000
TTM-1.039YOY-0.182-0.857
TTM-1.0395Y-0.886-0.153
5Y-0.88610Y-0.619-0.267
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.273-2.249+0.976
MRQ-1.039-2.553+1.514
TTM-1.039-2.669+1.630
YOY-0.182-4.107+3.925
5Y-0.886-6.247+5.361
10Y-0.619-6.499+5.880
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Lixte Biotechnology Holdings Inc:

  • The EOD is -1.509. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.231. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.231. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.509MRQ-1.231-0.278
MRQ-1.231TTM-1.2310.000
TTM-1.231YOY-0.248-0.983
TTM-1.2315Y-1.277+0.045
5Y-1.27710Y-0.885-0.391
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.509-2.858+1.349
MRQ-1.231-3.288+2.057
TTM-1.231-3.552+2.321
YOY-0.248-5.560+5.312
5Y-1.277-8.326+7.049
10Y-0.885-8.881+7.996
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Lixte is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.32 means the investor is paying $1.32 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Lixte Biotechnology Holdings Inc:

  • The EOD is 1.622. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.323. Based on the equity, the company is underpriced. +1
  • The TTM is 1.323. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.622MRQ1.323+0.298
MRQ1.323TTM1.3230.000
TTM1.323YOY0.222+1.102
TTM1.3235Y0.831+0.492
5Y0.83110Y1.066-0.235
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.6221.929-0.307
MRQ1.3232.090-0.767
TTM1.3232.091-0.768
YOY0.2222.881-2.659
5Y0.8313.545-2.714
10Y1.0663.936-2.870
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Lixte Biotechnology Holdings Inc.

3.1. Institutions holding Lixte Biotechnology Holdings Inc

Institutions are holding 5.081% of the shares of Lixte Biotechnology Holdings Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31HighTower Advisors, LLC4.42060.000499432994320
2023-12-31Morgan Stanley - Brokerage Accounts0.31590710600
2023-12-31FNY Investment Advisers, LLC0.24450.0133550050010
2023-12-31Tower Research Capital LLC0.09950.000122391180111.4259
2023-12-31Wells Fargo & Co0.00040900
2023-12-31UBS Group AG0.00010330
2023-12-31Ethos Financial Group LLC000-24808-100
2023-09-30Geode Capital Management, LLC000-10119-100
2023-12-31JPMorgan Chase & Co000-1-100
Total 5.0810.0138114289+66187+57.9%

3.2. Funds holding Lixte Biotechnology Holdings Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Fidelity Extended Market Index0.32980.0001741900
2024-03-31Vanguard Institutional Extnd Mkt Idx Tr0.23160520900
2024-02-29Fidelity Nasdaq Composite Index0.11470257900
2024-03-31NT Ext Equity Mkt Idx Fd - L0.0096021500
2023-12-31Northern Trust Extended Eq Market Idx0.0096021500
2023-12-31SSgA U.S. Extended Market Index Class I0.0084019000
2024-03-31State St US Extended Mkt Indx NL Cl C0.0084019000
2023-12-31SSgA U.S. Total Market Index Strategy0.0024055-1-1.7857
Total 0.71450.000116072-10.0%

3.3. Insider Transactions

Insiders are holding 20.482% of the shares of Lixte Biotechnology Holdings Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-10-03Der Baan Bastiaan Jeroen VanBUY100002.8

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Lixte Biotechnology Holdings Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.520-0.5200%0.167-412%-0.012-98%0.167-411%
Book Value Per Share--1.7761.7760%2.296-23%1.903-7%1.214+46%
Current Ratio--13.47913.4790%14.084-4%15.951-15%11.002+23%
Debt To Asset Ratio--0.0730.0730%0.071+3%0.067+9%0.214-66%
Debt To Equity Ratio--0.0790.0790%0.076+3%0.072+9%0.375-79%
Dividend Per Share----0%-0%-0%0.000-100%
Eps---2.262-2.2620%-2.803+24%-2.118-6%-1.579-30%
Free Cash Flow Per Share---1.909-1.9090%-2.050+7%-1.499-21%-1.124-41%
Free Cash Flow To Equity Per Share---0.511-0.5110%0.235-317%0.403-227%0.370-238%
Gross Profit Margin--1.8231.8230%1.000+82%1.165+57%1.082+68%
Intrinsic Value_10Y_max---15.790--------
Intrinsic Value_10Y_min---26.074--------
Intrinsic Value_1Y_max---1.225--------
Intrinsic Value_1Y_min---2.126--------
Intrinsic Value_3Y_max---3.953--------
Intrinsic Value_3Y_min---6.848--------
Intrinsic Value_5Y_max---7.009--------
Intrinsic Value_5Y_min---12.037--------
Market Cap6477955.200+18%5285831.5005285831.5000%1144888.610+362%3553023.470+49%2174771.022+143%
Net Profit Margin----0%-0%-0%-1.4260%
Operating Margin----0%-0%-0%-1.3230%
Operating Ratio----0%-0%-0%1.423-100%
Pb Ratio1.622+18%1.3231.3230%0.222+497%0.831+59%1.066+24%
Pe Ratio-1.273-23%-1.039-1.0390%-0.182-83%-0.886-15%-0.619-40%
Price Per Share2.880+18%2.3502.3500%0.509+362%1.580+49%0.967+143%
Price To Free Cash Flow Ratio-1.509-23%-1.231-1.2310%-0.248-80%-1.277+4%-0.885-28%
Price To Total Gains Ratio-5.535-23%-4.516-4.5160%3.054-248%-2.335-48%1.694-367%
Quick Ratio--13.39313.3930%13.560-1%15.455-13%10.519+27%
Return On Assets---1.181-1.1810%-1.134-4%-1.031-13%-2.179+85%
Return On Equity---1.273-1.2730%-1.221-4%-1.107-13%-3.734+193%
Total Gains Per Share---0.520-0.5200%0.167-412%-0.012-98%0.167-411%
Usd Book Value--3994762.0003994762.0000%5165227.000-23%4279282.600-7%2731023.200+46%
Usd Book Value Change Per Share---0.520-0.5200%0.167-412%-0.012-98%0.167-411%
Usd Book Value Per Share--1.7761.7760%2.296-23%1.903-7%1.214+46%
Usd Dividend Per Share----0%-0%-0%0.000-100%
Usd Eps---2.262-2.2620%-2.803+24%-2.118-6%-1.579-30%
Usd Free Cash Flow---4293265.000-4293265.0000%-4611737.000+7%-3370695.800-21%-2527081.100-41%
Usd Free Cash Flow Per Share---1.909-1.9090%-2.050+7%-1.499-21%-1.124-41%
Usd Free Cash Flow To Equity Per Share---0.511-0.5110%0.235-317%0.403-227%0.370-238%
Usd Market Cap6477955.200+18%5285831.5005285831.5000%1144888.610+362%3553023.470+49%2174771.022+143%
Usd Price Per Share2.880+18%2.3502.3500%0.509+362%1.580+49%0.967+143%
Usd Profit---5087029.000-5087029.0000%-6304714.000+24%-4756174.200-7%-3547544.100-30%
Usd Revenue----0%-0%-0%20000.000-100%
Usd Total Gains Per Share---0.520-0.5200%0.167-412%-0.012-98%0.167-411%
 EOD+5 -3MRQTTM+0 -0YOY+12 -185Y+5 -2510Y+16 -18

4.2. Fundamental Score

Let's check the fundamental score of Lixte Biotechnology Holdings Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.273
Price to Book Ratio (EOD)Between0-11.622
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than113.393
Current Ratio (MRQ)Greater than113.479
Debt to Asset Ratio (MRQ)Less than10.073
Debt to Equity Ratio (MRQ)Less than10.079
Return on Equity (MRQ)Greater than0.15-1.273
Return on Assets (MRQ)Greater than0.05-1.181
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Lixte Biotechnology Holdings Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.086
Ma 20Greater thanMa 503.276
Ma 50Greater thanMa 1002.850
Ma 100Greater thanMa 2002.517
OpenGreater thanClose2.890
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets4,309
Total Liabilities314
Total Stockholder Equity3,995
 As reported
Total Liabilities 314
Total Stockholder Equity+ 3,995
Total Assets = 4,309

Assets

Total Assets4,309
Total Current Assets4,231
Long-term Assets78
Total Current Assets
Cash And Cash Equivalents 4,203
Other Current Assets 27
Total Current Assets  (as reported)4,231
Total Current Assets  (calculated)4,231
+/-0
Long-term Assets
Long-term Assets Other 78
Long-term Assets  (as reported)78
Long-term Assets  (calculated)78
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities314
Long-term Liabilities0
Total Stockholder Equity3,995
Total Current Liabilities
Short-term Debt -314
Accounts payable 157
Other Current Liabilities 314
Total Current Liabilities  (as reported)314
Total Current Liabilities  (calculated)157
+/- 157
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock0
Retained Earnings -48,482
Other Stockholders Equity 48,976
Total Stockholder Equity (as reported)3,995
Total Stockholder Equity (calculated)495
+/- 3,500
Other
Capital Stock3,500
Cash and Short Term Investments 4,203
Common Stock Shares Outstanding 1,916
Current Deferred Revenue157
Liabilities and Stockholders Equity 4,309
Net Debt -4,203
Net Invested Capital 495
Net Working Capital 3,995



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-31
> Total Assets 
5
751
629
52
1,601
1,931
430
1,753
558
539
598
433
1,368
4,337
2,672
5,228
5,093
5,560
4,309
4,3095,5605,0935,2282,6724,3371,3684335985395581,7534301,9311,601526297515
   > Total Current Assets 
5
750
628
52
1,601
1,931
430
1,753
558
539
598
433
1,368
4,334
2,672
5,228
5,093
5,560
4,231
4,2315,5605,0935,2282,6724,3341,3684335985395581,7534301,9311,601526287505
       Cash And Cash Equivalents 
5
680
508
10
1,544
119
14
1,655
475
44
25
200
1,306
4,273
2,599
5,069
4,824
5,353
4,203
4,2035,3534,8245,0692,5994,2731,30620025444751,655141191,544105086805
       Short-term Investments 
0
0
0
0
25
1,601
351
6
6
214
104
0
0
0
0
0
0
0
0
00000000104214663511,601250000
       Net Receivables 
0
0
0
0
0
116
0
0
0
0
200
0
0
0
14
0
0
0
0
000014000200000011600000
       Other Current Assets 
0
50
88
13
32
50
29
52
34
231
208
183
62
61
59
15
10
10
27
2710101559616218320823134522950321388500
   > Long-term Assets 
0
1
1
0
0
0
0
0
0
0
0
0
0
2
0
77
150
147
78
7814715077020000000000110
       Property Plant Equipment 
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000110
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
-77
-150
-147
0
0-147-150-77020000000000000
> Total Liabilities 
13
125
252
375
300
195
351
261
322
273
286
219
373
211
238
217
303
395
314
31439530321723821137321928627332226135119530037525212513
   > Total Current Liabilities 
13
125
252
375
300
195
351
261
322
273
286
219
373
211
238
217
303
395
314
31439530321723821137321928627332226135119530037525212513
       Short-term Debt 
0
0
0
100
0
0
0
153
119
35
-123
-59
-61
-211
-238
0
-303
-395
-314
-314-395-3030-238-211-61-59-12335119153000100000
       Accounts payable 
0
32
74
93
0
0
183
80
108
123
159
160
312
195
144
190
226
230
157
15723022619014419531216015912310880183009374320
       Other Current Liabilities 
13
93
178
182
300
195
167
14
47
58
125
59
61
211
238
10
303
395
314
3143953031023821161591255847141671953001821789313
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
238
206
303
395
0
039530320623800000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
0
0
0
0000020000000000000
> Total Stockholder Equity
-8
627
377
-324
1,301
1,736
79
1,492
236
266
312
215
995
4,126
2,434
5,012
4,790
5,165
3,995
3,9955,1654,7905,0122,4344,1269952153122662361,492791,7361,301-324377627-8
   Common Stock
0
3
3
3
3
4
4
4
4
5
5
5
6
7
7
1
1
2
0
0211776555444433330
   Retained Earnings -48,482-43,395-37,082-30,354-27,089-24,649-22,515-20,707-18,572-15,718-12,952-11,577-7,998-5,930-5,050-3,498-2,227-504-33
   Capital Surplus 0000000000000000000
   Treasury Stock0000000000000000000
   Other Stockholders Equity 
25
1,128
2,601
3,172
6,348
7,663
8,073
13,065
13,184
15,979
17,130
17,417
20,005
25,268
26,016
31,864
38,371
45,058
48,976
48,97645,05838,37131,86426,01625,26820,00517,41717,13015,97913,18413,0658,0737,6636,3483,1722,6011,12825



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-5,090
Operating Income-5,090-5,090
 
Operating Expense (+$)
Research Development898
Selling General Administrative4
Selling And Marketing Expenses4,188
Operating Expense5,0905,090
 
Net Interest Income (+$)
Interest Income21
Interest Expense-16
Other Finance Cost-7
Net Interest Income11
 
Pretax Income (+$)
Operating Income-5,090
Net Interest Income11
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-5,087-5,093
EBIT - interestExpense = -5,112
-5,092
-5,071
Interest Expense16
Earnings Before Interest and Taxes (EBIT)-5,095-5,071
Earnings Before Interest and Taxes (EBITDA)-5,090
 
After tax Income (+$)
Income Before Tax-5,087
Tax Provision-0
Net Income From Continuing Ops-5,686-5,087
Net Income-5,087
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses5,090
Total Other Income/Expenses Net3-11
 

Technical Analysis of Lixte
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Lixte. The general trend of Lixte is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Lixte's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Lixte Biotechnology Holdings Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 3.59 < 4.32 < 4.4.

The bearish price targets are: 2.84 > 2.818 > 2.61.

Tweet this
Lixte Biotechnology Holdings Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Lixte Biotechnology Holdings Inc. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Lixte Biotechnology Holdings Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Lixte Biotechnology Holdings Inc. The current macd is 0.03245987.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Lixte price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Lixte. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Lixte price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Lixte Biotechnology Holdings Inc Daily Moving Average Convergence/Divergence (MACD) ChartLixte Biotechnology Holdings Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Lixte Biotechnology Holdings Inc. The current adx is 34.02.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Lixte shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Lixte Biotechnology Holdings Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Lixte Biotechnology Holdings Inc. The current sar is 4.06851109.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Lixte Biotechnology Holdings Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Lixte Biotechnology Holdings Inc. The current rsi is 44.09. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
Lixte Biotechnology Holdings Inc Daily Relative Strength Index (RSI) ChartLixte Biotechnology Holdings Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Lixte Biotechnology Holdings Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Lixte price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Lixte Biotechnology Holdings Inc Daily Stochastic Oscillator ChartLixte Biotechnology Holdings Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Lixte Biotechnology Holdings Inc. The current cci is -251.92037697.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Lixte Biotechnology Holdings Inc Daily Commodity Channel Index (CCI) ChartLixte Biotechnology Holdings Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Lixte Biotechnology Holdings Inc. The current cmo is -24.03187756.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Lixte Biotechnology Holdings Inc Daily Chande Momentum Oscillator (CMO) ChartLixte Biotechnology Holdings Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Lixte Biotechnology Holdings Inc. The current willr is -85.54216867.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Lixte Biotechnology Holdings Inc Daily Williams %R ChartLixte Biotechnology Holdings Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Lixte Biotechnology Holdings Inc. The current atr is 0.30858237.

Lixte Biotechnology Holdings Inc Daily Average True Range (ATR) ChartLixte Biotechnology Holdings Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Lixte Biotechnology Holdings Inc. The current obv is 38,334,512.

Lixte Biotechnology Holdings Inc Daily On-Balance Volume (OBV) ChartLixte Biotechnology Holdings Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Lixte Biotechnology Holdings Inc. The current mfi is 39.98.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Lixte Biotechnology Holdings Inc Daily Money Flow Index (MFI) ChartLixte Biotechnology Holdings Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Lixte Biotechnology Holdings Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-19MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-26MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-25STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-05-01STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Lixte Biotechnology Holdings Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Lixte Biotechnology Holdings Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.086
Ma 20Greater thanMa 503.276
Ma 50Greater thanMa 1002.850
Ma 100Greater thanMa 2002.517
OpenGreater thanClose2.890
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Lixte with someone you think should read this too:
  • Are you bullish or bearish on Lixte? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Lixte? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Lixte Biotechnology Holdings Inc

I send you an email if I find something interesting about Lixte Biotechnology Holdings Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Lixte Biotechnology Holdings Inc.

Receive notifications about Lixte Biotechnology Holdings Inc in your mailbox!